Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Alisa M. Higgins et al.
Summary: The longer-term effects of therapies for critically ill COVID-19 patients are unknown. In this study, 4869 patients were randomized to receive different interventions, and it was found that treatment with IL-6 receptor antagonists and antiplatelet agents significantly improved survival rates after 180 days. These findings suggest that most therapies have consistent effects over a 6-month period.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2023)
Article
Immunology
Waasila Jassat et al.
Summary: Admission incidence risk and in-hospital mortality decreased in the Omicron BA.1/BA.2 and Omicron BA.4/BA.5 waves. Mortality risk was lower in those with natural infection and vaccination, declining further as the number of vaccine doses increased.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Medicine, General & Internal
Jay J. H. Park et al.
Summary: Platform trials are a type of randomized clinical trial that allow simultaneous comparison of multiple intervention groups against a single control group. This approach has the advantage of efficiency and flexibility, enabling rapid therapeutic discoveries and addressing critical clinical questions. Platform trials have been widely used in investigating evolving therapies for COVID-19.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Multidisciplinary Sciences
Bo Meng et al.
Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.
Article
Medicine, General & Internal
R. L. Gottlieb et al.
Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Editorial Material
Medicine, General & Internal
Jean M. Connors et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Medicine, General & Internal
Charlotte A. Bradbury et al.
Summary: The study results showed that among critically ill patients with COVID-19, treatment with an antiplatelet agent compared with no antiplatelet agent did not significantly improve the number of organ support-free days within 21 days. The use of antiplatelet therapy in critically ill patients with COVID-19 did not show significant benefits.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Etheresia Pretorius et al.
Summary: Fibrin amyloid microclots and platelet hyperactivation in South African patients with Long COVID/PASC may be responsible for the persistent symptoms. Hypertension, high cholesterol levels, cardiovascular disease, and type 2 diabetes mellitus were found to be the most important comorbidities. The study highlights the need for further research on the pathophysiology and treatment of Long COVID/PASC.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Medicine, General & Internal
Anthony C. Gordon et al.
Summary: Interleukin-6 receptor antagonists tocilizumab and sarilumab were found to improve outcomes, including survival, in critically ill patients with Covid-19 receiving organ support in ICUs according to an ongoing international trial. The efficacy of these treatments has been confirmed, with patients benefiting from the therapy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Patrick R. Lawler et al.
Summary: This study showed that therapeutic-dose anticoagulation with heparin in non-critically ill patients with Covid-19 increased the likelihood of survival to hospital discharge and reduced the need for cardiovascular or respiratory organ support compared to usual-care thromboprophylaxis.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Medicine, General & Internal
Bhagteshwar Singh et al.
Summary: The study evaluated the effects of chloroquine and hydroxychloroquine in treating and preventing COVID-19. Results showed that these drugs did not significantly impact the death rate or virus clearance time in infected patients, while they may increase the risk of adverse events.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
(2021)
Article
Medicine, General & Internal
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
